Skip to main content

Advertisement

Table 1 Baseline characteristics and antibody positivity

From: Baseline autoantibody profile in rheumatoid arthritis is associated with early treatment response but not long-term outcomes

  Baseline (N = 356) 8 months (N = 209)
RA (2010 criteria), n (%) 356 (100%) -
Female sex, n (%) 243 (68%) -
Age, mean years (SD) 51.2 (13.2) -
Symptom duration (weeks), median (IQR) 18 (9-35)a -
Ever smokers 165 (47%)a -
DAS, mean ± SD 3.3 (0.9) -
Anti-CCP2 IgG, n (%) 292 (82%) 168 (80%)
Anti-CCP2 IgM, n (%) 146 (41%) 62 (30%)
Anti-CCP2 IgA, n (%) 150 (42%) 58 (28%)
RF IgM, n (%) 267 (75%) 121 (58%)
RF IgA, n (%) 212 (60%)a 84 (40%)a
Anti-CarP IgG, n (%) 175 (49%) 64 (31%)
Anti-CarP IgM, n (%) 141 (40%) 35 (17%)
Anti-CarP IgA, n (%) 109 (32%)a 23 (11%)
Anti-cetyl-Lysine IgG, n (%) 130 (37%) 67 (32%)
Anti-Acetyl-Ornithine IgG, n (%) 252 (71%) 132 (63%)
Anti-Cit-Vim IgG, n (%) 208 (58%) 100 (48%)
Anti-Cit-Fib α IgG, n (%) 101 (28%) 29 (14%)
Anti-Cit-Fib β IgG, n (%) 213 (60%) 105 (50%)
Anti-Cit-Eno IgG, n (%) 115 (32%) 58 (28%)
Number of isotypes, median (IQR) 4 (2–6)a 3 (1–4)a
Number of AMPAs, median (IQR) 4 (2–-6) 4 (2–5)
  1. Vim vimentin, Fib fibrinogen, Eno enolase, IQR interquartile range, Lys lysine, Orn ornithine, SD standard deviation
  2. aSome missing values. See Fig. 1 for number of data available on individual antibody measurements. Available data for symptom duration and smoking, n = 355; for anti-CarP IgA, n = 344 at baseline; for number of isotypes n = 343 at baseline; n = 208 at 8 months